The DOI matches its Crossref record.
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Mechanisms of resistance to cisplatin and carboplatin
Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631
Cisplatin resistance: Preclinical findings and clinical implications
Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361
Köberle, B., Masters, J. R. W., Hartley, J. A., & Wood, R. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80118-3 · Cited by 300
Zeron-Medina, J., Wang, X., Repapi, E., Campbell, M. R., Su, D., Castro-Giner, F., Davies, B., Peterse, E. F. P., Sacilotto, N., Walker, G. J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.017 · Cited by 118
“Intriguingly, 80% of testicular germ cell tumors can be cured with DNA-damaging therapies, and the retention of p53 activity has been implicated in this astounding cure rate through chemotherapeutics (Bosl andMotzer, 1997; Gutekunst et al., 2011; Houldsworth et al., 1998; Masters and Köberle, 2003).”
Targeting p53-null neuroblastomas through RLIP76
Singhal, J., Yadav, S., Nagaprashantha, L. D., Vatsyayan, R., Singhal, S. S., & Awasthi, S. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0025 · Cited by 25
Metadata
- Authors
- Houldsworth, J., Xiao, H., Murty, V., Chen, W., Ray, B., Reuter, V. E., Bosl, G. J., & Chaganti, R.
- Venue
- Oncogene
- Published
- 1998-05-07
- Volume
- 16
- Issue
- 18
- Pages
- 2345-2349
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2320028767
- Cited by
- 161
- References
- 0
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.